The cost-effectiveness of exenatide twice daily (BID) versus insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.
CONCLUSIONS: The addition of exenatide BID rather than insulin lispro to basal insulin is associated with similar or better clinical outcomes. Illustrated from the Swedish healthcare perspective, analysis with the Cardiff Diabetes Model demonstrated that exenatide BID represents a cost-effective treatment alternative to lispro TID as add-on therapy in type 2 diabetes patients insufficiently controlled on basal insulin.
PMID: 27356188 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - June 30, 2016 Category: Health Management Tags: J Med Econ Source Type: research
Comparison of Insulin Lispro Mix 25 with Insulin Lispro Mix 50 as Insulin Starter in Chinese Patients with Type 2 Diabetes Mellitus (CLASSIFY Study): A Subgroup Analysis of a Phase 4, Open‐Label, Randomized Trial
ConclusionsIn Chinese patients with T2DM, LM50 was more efficacious than LM25 as starter insulin. (Source: Journal of Diabetes)
Source: Journal of Diabetes - June 30, 2016 Category: Endocrinology Authors: Qing Su, Chao Liu, Hongting Zheng, Jun Zhu, Peng Fei Li, Lei Qian, Wen Ying Yang Tags: Original Article Source Type: research
Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin
Conclusions:
Based on these key attributes, the IL 200 pen was significantly preferred over the IL 100 pen by patients with diabetes who require >20 daily mealtime insulin units or diabetes caregivers and may improve the injection experience for these patients. (Source: Journal of Diabetes Science and Technology)
Source: Journal of Diabetes Science and Technology - June 27, 2016 Category: Endocrinology Authors: Wang, T., Conrad, K. A., van Brunt, K., Rees, T. M. Tags: Original Articles Source Type: research
Randomized double ‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
ConclusionsIn patients with T2D, BIL with insulin lispro provided greater improvement in glycaemic control with less nocturnal hypoglycaemia, lower glucose variability and less weight gain compared with glargine. The daytime hypoglycaemia rate and mean triglyceride and aminotransferase levels were higher with BIL. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 23, 2016 Category: Endocrinology Authors: T. Blevins, T. R. Pieber, G. Col ón Vega, S. Zhang, E. J. Bastyr, A. M. Chang, Tags: ORIGINAL ARTICLE Source Type: research
Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
ConclusionsIn patients with T2D, BIL with insulin lispro provided greater improvement in glycaemic control with less nocturnal hypoglycaemia, lower glucose variability and less weight gain compared with glargine. The daytime hypoglycaemia rate and mean triglyceride and aminotransferase levels were higher with BIL. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 23, 2016 Category: Endocrinology Authors: T. Blevins, T. R. Pieber, G. Colón Vega, S. Zhang, E. J. Bastyr, A. M. Chang, Tags: ORIGINAL ARTICLE Source Type: research
Pharmacokinetics and pharmacodynamics of insulin glargine –insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
Conclusions Glargine/glulisine pharmacokinetics in type 1 diabetes can closely approximate physiologic insulin responses in healthy individuals during a day in which three standardized meals are consumed. Additionally, when glulisine is dosed only five minutes pre-meal, systemic insulin concentration rises as rapidly as prandial endogenous insulin levels. This present study compared glargine and glulisine administered in an approximate 50/50 proportion. Future studies of alternate meal times, meal content and differing premixed insulin preparations are indicated. (Source: Journal of Clinical and Translational Endocrinology)
Source: Journal of Clinical and Translational Endocrinology - June 17, 2016 Category: Endocrinology Source Type: research
Continuous Glucose Monitoring in Type 2 Diabetes Patients Treated with GLP ‐1 Receptor Agonist Dulaglutide in Combination with Prandial Insulin Lispro – An AWARD‐4 Substudy
ConclusionsIn combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycaemic range, but dulaglutide provided an improved balance between the proportion of values within the near‐normoglycaemia range and values within the hypoglycaemic range. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 8, 2016 Category: Endocrinology Authors: Johan Jendle, Marcia A. Testa, Sherry Martin, Honghua Jiang, Zvonko Milicevic Tags: ORIGINAL ARTICLE Source Type: research
A Randomized, Double ‐Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 3
ConclusionsIn patients with type 1 diabetes, treatment with BIL compared to GL for 52 weeks resulted in a lower HbA1c, more patients with HbA1c<7%, and reduced nocturnal hypoglycemia, but more total hypoglycemia and injection site reactions and higher triglycerides and ALT.(Funded by Eli Lilly and Company, ClinicalTrials.gov number NCT01454284.)Clinical trial registry number: NCT01454284 (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 5, 2016 Category: Endocrinology Authors: Richard M. Bergenstal, Helen Lunt, Edward Franek, Florence Travert, Jiani Mou, Yongming Qu, Caryl J. Antalis, Mark L. Hartman, Myriam Rosilio, Scott J. Jacober, Edward J Bastyr, Tags: ORIGINAL ARTICLE Source Type: research
A Randomized, Double‐Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial Insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 3
ConclusionsIn patients with type 1 diabetes, treatment with BIL compared to GL for 52 weeks resulted in a lower HbA1c, more patients with HbA1c<7%, and reduced nocturnal hypoglycemia, but more total hypoglycemia and injection site reactions and higher triglycerides and ALT.(Funded by Eli Lilly and Company, ClinicalTrials.gov number NCT01454284.)Clinical trial registry number: NCT01454284 (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 5, 2016 Category: Endocrinology Authors: Richard M. Bergenstal, Helen Lunt, Edward Franek, Florence Travert, Jiani Mou, Yongming Qu, Caryl J. Antalis, Mark L. Hartman, Myriam Rosilio, Scott J. Jacober, Edward J Bastyr, Tags: ORIGINAL ARTICLE Source Type: research
Continuous Glucose Monitoring in Type 2 Diabetes Patients Treated with GLP‐1 Receptor Agonist Dulaglutide in Combination with Prandial Insulin Lispro – An AWARD‐4 Substudy
ConclusionsIn combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycaemic range, but dulaglutide provided an improved balance between the proportion of values within the near‐normoglycaemia range and values within the hypoglycaemic range. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - May 31, 2016 Category: Endocrinology Authors: Johan Jendle, Marcia A. Testa, Sherry Martin, Honghua Jiang, Zvonko Milicevic Tags: ORIGINAL ARTICLE Source Type: research
Randomized, Double‐Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination With Prandial Insulin Lispro, in Patients with Type 2 Diabetes: IMAGINE 4
ConclusionsIn T2D patients, BIL vs glargine, with insulin lispro, provided greater improvement in glycemic control with less nocturnal hypoglycemia, lower glucose variability, and less weight gain. Daytime hypoglycemia rate, mean triglyceride, and aminotransferase levels were higher with BIL.Clinical trial registry number: NCT01468987 (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - May 28, 2016 Category: Endocrinology Authors: Thomas Blevins, Thomas R. Pieber, Gildred Colón Vega, Shuyu Zhang, Edward J. Bastyr III, Annette M. Chang, Tags: ORIGINAL ARTICLE Source Type: research
What is the role of concentrated insulin in diabetes management?
ABSTRACT: Two concentrated analog insulins, long-acting insulin glargine U-300 (Toujeo) and rapid-acting insulin lispro (Humalog U-200), were recently approved by the FDA. Providers must be aware of clinical differences in these new product formulations compared with their nonconcentrated formulations, so that they can select appropriate patients for these products and minimize drug errors. (Source: Journal of the American Academy of Physician Assistants)
Source: Journal of the American Academy of Physician Assistants - May 27, 2016 Category: Primary Care Tags: Pharmacology Consult Source Type: research
Insulin and Lispro Insulin: What is Common and Different in Their Behavior?
Abstract
There are different insulin analogues with various pharmacokinetic characteristics, such as, rapid-acting, long-acting, or intermediate-acting analogues. Since insulin tends to form amyloid aggregates, it is of particular interest to measure characteristic times of formation of amyloid aggregates and compare those to action times for insulin and its analogues. For the study we have chosen one of the insulin analogues - insulin Lispro, which is a fast acting insulin analog. It is usually thought of amyloid aggregation as a nucleation-dependent process. We have estimated the size of the primary nucl...
Source: Current Protein and Peptide Science - May 25, 2016 Category: Biochemistry Authors: Selivanova OV, Suvorina MY, Surin AK, Dovidchenko NV, Galzitskaya O Tags: Curr Protein Pept Sci Source Type: research
Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open‐label, randomized trial (CLASSIFY study)
ConclusionsLM25 and LM50 were noninferior to each other in improving glycemic control in Asian patients with type 2 diabetes. In addition, LM50 was more efficacious than LM25 with respect to the percentage of subjects reaching target HbA1c levels. (Source: Diabetes/Metabolism Research and Reviews)
Source: Diabetes/Metabolism Research and Reviews - May 6, 2016 Category: Endocrinology Authors: Hirotaka Watada, Qing Su, Peng Fei Li, Noriyuki Iwamoto, Lei Qian, Wen Ying Yang Tags: Research Article Source Type: research
Hypoglycemic treatment of diabetic patients in the Emergency Department.
CONCLUSIONS: We found antidiabetic prescriptions to have a low adaptation to consensus recommendations. These results are in line with other studies, showing an abuse of sliding scale regimen as single hypoglycemic treatment.
PMID: 27145387 [PubMed - as supplied by publisher] (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - May 6, 2016 Category: Drugs & Pharmacology Authors: Caballero Requejo C, Urbieta Sanz E, Trujillano Ruiz A, García-Molina Sáez C, Onteniente Candela M, Piñera Salmerón P Tags: Farm Hosp Source Type: research
